Stocks in Play: ardiol Therapeutics Inc.
Wednesday, April 16, 2025
10:53 AM EST - ardiol Therapeutics Inc. : Announced today that Northwestern University has enrolled the first patient in the pivotal Phase III MAVERIC trial ("MAVERIC") evaluating Cardiol's lead drug candidate CardiolRx™ for the prevention of recurrent pericarditis. This multi-center, randomized, double-blind, placebo-controlled trial is designed to definitively assess the impact of CardiolRx™ on preventing recurrent pericarditis in patients at high risk for disease relapse and to support regulatory approval. Cardiol Therapeutics Inc. (T.CRDL) shares were up $0.01 at 1.48.Stocks in Play: ardiol Therapeutics Inc. , Wed, 16 Apr 2025 10:57:06 EST
